Aller au contenu principal

Tous les comptes rendus : mercredi 25 septembre 2013

Études d'intervention

Vers un autre protocole de basal bolus ?

B Wolffenbuttell et coll. - Glycemic control and hypoglycemia in metformin treated T2DM patients with Exenatide BID vs insulin Lispro TID added to titrated insulin Glargine QD: the 4B TRIAL.

Recherche

Un agoniste mixte GLP-gastrine !

J. Skarbaliene et coll. - PS 518. Effects of a novel GLP-1-gastrin dual agonist, ZP3022, on beta cell proliferation, apoptosis and functional capacity. - Communications affichées : session "Beta cell mass expansion and survival".

Complications/comorbidités

Comment les patients diabétiques de type 2 avec insuffisance rénale sont-ils évalués et suivis en France ?

J.-F. Blicklé et coll. - J.-F. Blicklé et coll. PS 271. How are patients with type 2 diabetes and renal disease monitored and managed in France ? - Communications affichées : session "Managing and monitoring diabetes: who does well and who doesn’t?"

Thérapeutique

Les dessous de l’inertie thérapeutique

B. Balkau et coll. - Poster 001. Managing and monitoring diabetes: who does well and who doesn’t? Reasons for non-intensification of therapy in type 2 diabetes patients uncontrolled by oral monotherapy in general pratice in France: The DIAttitude study.

Thérapeutique

Maintien de l’efficacité de la dapagliflozine à 4 ans

A. Langkilde - Poster Hall PSO73. SGPL-2 clinical trials. Durability of dapaglifozin vs glipizide as add-on therapies in type 2 diabetes inadaquately controlled on metformine.

Facteurs de risque

DT2 et polluants : la piste se confirme ?

B. Le Magueresse-Battistoni et coll. - Poster 321. A chronic exposure to a mixture of low-dosed food contaminants predisposes to the risk of developping metabolic disorders.